Inhaled Heparin for Hospitalised Patients With Coronavirus Disease 2019 (COVID-19)

NCT ID: NCT05184101

Last Updated: 2024-02-26

Basic Information

• Recruitment Status: WITHDRAWN
• Clinical Phase: PHASE2/PHASE3
• Study Classification: INTERVENTIONAL
• Study Start Date: 2023-08-31
• Study Completion Date: 2024-03-01

Brief Summary

Investigator-initiated, multi-centre, randomised, open-label trial of nebulised heparin sodium in addition to standard care compared to standard care alone in hospitalised patients with COVID-19 infection.

Detailed Description

Heparin has been used as a medicine for over 75 years. It is used mostly as an anticoagulant (blood thinner), injected under the skin or infused into a vein to prevent or treat large blood clots.

Most patients who are eligible for this study are already receiving heparin administered under the skin or into a vein, and this treatment would continue after enrolment in the study, as determined by the treating doctors according to best practice.

In this study heparin is administered using a nebuliser. A nebuliser is a device that changes a fluid into a mist of tiny droplets so it can be easily breathed into the lungs. A nebuliser is a commonly used and effective way of giving medications that work in the lungs. Nebulised heparin is not currently a standard treatment, but there are good reasons to think it could help.

Lung infections, including COVID-19, cause the widespread formation of tiny blood clots in the small blood vessels and air sacs of the lungs, which make breathing difficult and lead to lung damage. Previous studies of patients with serious breathing problems due to pneumonia and other conditions found that nebulised heparin reduced the formation of small blood clots in the lungs, reduced the amount of injury to the lungs and hastened recovery with faster return to living at home. The virus that causes COVID-19 (the SARS-CoV-2 virus) has 'spikes' on its surface that enable it to attach to cells of the body and enter those cells. Another way that nebulised heparin might help is by sticking to these spikes on the virus and inhibiting the ability of the virus to enter the cells.

The main aim is to determine if nebulised heparin reduces the chance that a patient needs help with their breathing from a mechanical ventilator. Other aims are to determine if nebulised heparin increases the chances of surviving and of getting better quicker.

Conditions

COVID-19

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: SINGLE

Study Groups

Nebulised heparin

Participants assigned to 'nebulised heparin' will receive nebulised heparin in addition to the standard care required as determined by the treating team.

Group Type: EXPERIMENTAL

Unfractionated Heparin

Intervention Type: DRUG

Heparin sodium will be administered as a nebulised aerosol dose of 25,000 IU heparin three times a day (TDS) via an Aerogen Solo (Aerogen, Ireland) vibrating mesh aerosol drug nebulizer.

Standard care

Participants assigned to 'standard care' will receive the standard care required as determined by the treating team and will not be treated with nebulised heparin.

Group Type: NO_INTERVENTION

No interventions assigned to this group

Interventions

Unfractionated Heparin

Heparin sodium will be administered as a nebulised aerosol dose of 25,000 IU heparin three times a day (TDS) via an Aerogen Solo (Aerogen, Ireland) vibrating mesh aerosol drug nebulizer.

Intervention Type: DRUG

Other Intervention Names

Heparin

Eligibility Criteria

Inclusion Criteria

• Age 18 years or older
• Currently admitted to hospital
• There is a positive sample for COVID-19 within the past 14 days. The sample can be a nasal or pharyngeal swab, sputum, tracheal aspirate, bronchoalveolar lavage, or another sample from the patient
• Requiring oxygenation according to the modified ordinal clinical scale 4-5

Exclusion Criteria

• Intubated and on mechanical ventilation, or requiring immediate intubation as per the treating clinician's assessment
• Heparin allergy or heparin-induced thrombocytopaenia
• Activated partial thromboplastin time (APTT) > 120 seconds, not due to anticoagulant therapy and does not correct with administration of fresh frozen plasma
• Platelet count < 20 x 10^9 per L within 48 hours of randomisation
• Pulmonary bleeding or uncontrolled bleeding within 48 hours of randomisation
• Known or suspected pregnancy
• Acute brain injury that may result in long-term disability
• Myopathy, spinal cord injury, or nerve injury or disease with a likely prolonged incapacity to breathe independently e.g. Guillain-Barre syndrome
• Treatment limitations in place, i.e. not for intubation, not for ICU admission
• Death is imminent or inevitable within 24 hours
• Clinician objection
• Participant consent declined

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

The George Institute

OTHER

Sponsor Role: collaborator

St George Hospital, Australia

OTHER

Sponsor Role: collaborator

St Vincent's Hospital Melbourne

OTHER

Sponsor Role: collaborator

John Hunter Hospital

OTHER_GOV

Sponsor Role: collaborator

Royal North Shore Hospital

OTHER

Sponsor Role: collaborator

Australian National University

OTHER

Sponsor Role: lead

Responsible Party

Frank van Haren

Professor

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Frank MP van Haren, PhD

Role: PRINCIPAL_INVESTIGATOR

Australian National University

Locations

St George Hospital

Kogarah, New South Wales, Australia

Countries

Australia

References

van Haren FMP, Page C, Laffey JG, Artigas A, Camprubi-Rimblas M, Nunes Q, Smith R, Shute J, Carroll M, Tree J, Carroll M, Singh D, Wilkinson T, Dixon B. Nebulised heparin as a treatment for COVID-19: scientific rationale and a call for randomised evidence. Crit Care. 2020 Jul 22;24(1):454. doi: 10.1186/s13054-020-03148-2.

Reference Type: BACKGROUND

PMID: 32698853 (View on PubMed)

van Haren FMP, Richardson A, Yoon HJ, Artigas A, Laffey JG, Dixon B, Smith R, Vilaseca AB, Barbera RA, Ismail TI, Mahrous RS, Badr M, De Nucci G, Sverdloff C, van Loon LM, Camprubi-Rimblas M, Cosgrave DW, Smoot TL, Staas S, Sann K, Sas C, Belani A, Hillman C, Shute J, Carroll M, Wilkinson T, Carroll M, Singh D, Page C. INHALEd nebulised unfractionated HEParin for the treatment of hospitalised patients with COVID-19 (INHALE-HEP): Protocol and statistical analysis plan for an investigator-initiated international metatrial of randomised studies. Br J Clin Pharmacol. 2021 Aug;87(8):3075-3091. doi: 10.1111/bcp.14714. Epub 2021 Jan 19.

Reference Type: BACKGROUND

PMID: 33377218 (View on PubMed)

Other Identifiers

INHALE-HEP Australia Version 3

Identifier Type: -

Identifier Source: org_study_id